Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Erratum

Erratum to: The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells

Authors: Konrad Steinestel, Stefan Eder, Konstantin Ehinger, Juliane Schneider, Felicitas Genze, Eva Winkler, Eva Wardelmann, Andres J. Schrader, Julie Steinestel

Published in: Tumor Biology | Issue 2/2016

Login to get access

Excerpt

Erratum to: Tumor Biol. …
Metadata
Title
Erratum to: The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells
Authors
Konrad Steinestel
Stefan Eder
Konstantin Ehinger
Juliane Schneider
Felicitas Genze
Eva Winkler
Eva Wardelmann
Andres J. Schrader
Julie Steinestel
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4659-5

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Review

Decreased expression of MEG3 contributes to retinoblastoma progression and affects retinoblastoma cell growth by regulating the activity of Wnt/β-catenin pathway

Original Article

The upregulated α-catulin expression was involved in head-neck squamous cell carcinogenesis by promoting proliferation, migration, invasion, and epithelial to mesenchymal transition

Original Article

Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib

Original Article

CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway

Original Article

Evaluation of GWAS-identified SNPs at 6p22 with neuroblastoma susceptibility in a Chinese population

Original Article

Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits